SparX Therapeutics
SparX Biopharmaceutical Corp. is a research-based development-stage biopharmaceutical company dedicated to strengthening human immunity through the discovery and development of innovative immuno-oncology agents, including antibody therapies and ADC platforms. The company focuses on targeting multiple pathways in cancer treatment and advancing next-generation immuno-oncology strategies.
Industries
Nr. of Employees
medium (51-250)
SparX Therapeutics
700 E. Business Center Dr. Mount Prospect, IL 60056
Products
LILRB2/PD-L1 bispecific antibody (clinical-stage)
A clinical-stage bispecific antibody targeting LILRB2 and PD-L1, developed for treatment of advanced solid tumors and evaluated in Phase I studies.
Nano-domain bifunctional biparatopic ADC (preclinical/experimental)
An experimental bifunctional biparatopic ADC constructed from small-domain binders intended to enhance target specificity and payload delivery.
LILRB2/PD-L1 bispecific antibody (clinical-stage)
A clinical-stage bispecific antibody targeting LILRB2 and PD-L1, developed for treatment of advanced solid tumors and evaluated in Phase I studies.
Nano-domain bifunctional biparatopic ADC (preclinical/experimental)
An experimental bifunctional biparatopic ADC constructed from small-domain binders intended to enhance target specificity and payload delivery.
Services
Discovery and design services for multi-specific and bispecific antibody formats from target pairing through optimization.
Platform services for design, conjugation and preclinical evaluation of antibody–drug conjugates and bifunctional ADC constructs.
cGMP-compliant drug substance production including cell line support, upstream/downstream process execution and lot release activities.
Preclinical program support to generate data packages for regulatory submissions including safety and efficacy studies.
Clinical trial execution services for first-in-human and Phase I studies, including regulatory coordination and clinical data reporting.
Structuring and executing collaborative research agreements with industry and academic partners to advance therapeutic candidates.
Discovery and design services for multi-specific and bispecific antibody formats from target pairing through optimization.
Platform services for design, conjugation and preclinical evaluation of antibody–drug conjugates and bifunctional ADC constructs.
cGMP-compliant drug substance production including cell line support, upstream/downstream process execution and lot release activities.
Preclinical program support to generate data packages for regulatory submissions including safety and efficacy studies.
Clinical trial execution services for first-in-human and Phase I studies, including regulatory coordination and clinical data reporting.
Structuring and executing collaborative research agreements with industry and academic partners to advance therapeutic candidates.
Expertise Areas
- Immuno-oncology therapeutics
- Antibody engineering and multispecific formats
- Antibody–drug conjugate (ADC) development
- Biologics CMC and cGMP manufacturing
Key Technologies
- Multi-specific antibody discovery platforms
- Single-domain antibody selection
- Bispecific antibody engineering
- Antibody–drug conjugation techniques
News & Updates
SparX announced a research agreement with Mitsubishi Tanabe Pharma America to develop ADCs.
SparX will present clinical updates on SPX-303, an anti-LILRB2/PD-L1 bispecific antibody, at AACR 2025.
SparX unveiled its Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC).
First patient dosed with SPX-303, a bispecific antibody drug.
FDA approved IND application for SPX-303.
Collaboration with Arovella Therapeutics for cell therapy development.
SparX announced a research agreement with Mitsubishi Tanabe Pharma America to develop ADCs.
SparX will present clinical updates on SPX-303, an anti-LILRB2/PD-L1 bispecific antibody, at AACR 2025.
SparX unveiled its Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC).
First patient dosed with SPX-303, a bispecific antibody drug.
FDA approved IND application for SPX-303.
Collaboration with Arovella Therapeutics for cell therapy development.